To test this, we obtained data from two independent cohorts from the Alzheimer’s disease neuroimaging initiative (ADNI, N = 261) and the A05 cohort (N = 111) covering healthy controls (i.e., cognitively normal Aβ−) and AD-spectrum patients (i.e., Aβ+) with baseline flortaucipir tau-PET and amyloid-PET. This evidence concerns the gene MAPT and Alzheimer disease.